Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.

Genes, Neoplasm IMMUNOHISTOCHEMISTRY Lung Neoplasms Pathology, Molecular

Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
01 Dec 2022
Historique:
received: 07 09 2022
accepted: 21 11 2022
entrez: 1 12 2022
pubmed: 2 12 2022
medline: 2 12 2022
Statut: aheadofprint

Résumé

Pulmonary enteric adenocarcinoma (PEAC) is a rare variant of pulmonary adenocarcinoma. Due to its rarity, few pathological and molecular studies have been performed on PEAC. We herein conducted clinicopathological, immunohistochemical and molecular analyses of PEAC with a focus on its differentiation from invasive mucinous adenocarcinoma (IMA). We examined the clinicopathological features of 16 cases of PEAC and performed a genetic analysis using next-generation sequencing (NGS). The results obtained were compared with those for IMA. The average age of patients with PEAC (seven men and nine women) was 72.9 years. A comparison of clinical data on PEAC and IMA revealed no significant differences in age, sex or smoking history. Fifteen PEAC cases had dirty necrosis. Immunohistochemically, the positive rates for each antibody in PEAC were as follows: CK7, 88% (14/16); CK20, 81% (13/16); CDX2, 88% (14/16); p53, 69% (11/16); MUC1, 100% (16/16); MUC2, 19% (3/16); MUC5AC, 69% (11/16); MUC6, 19% (3/16). The positive rates for these antibodies in IMA were 100%, 87%, 0%, 7%, 93%, 0%, 100% and 80%, respectively. The rates of dirty necrosis, immunopositivity for CDX2 and

Identifiants

pubmed: 36456172
pii: jcp-2022-208583
doi: 10.1136/jcp-2022-208583
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Fumi Okada (F)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Maiko Takeda (M)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan maikot@naramed-u.ac.jp.

Tomomi Fujii (T)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Tomoko Uchiyama (T)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Shoh Sasaki (S)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Minami Matsuoka (M)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Yuji Nitta (Y)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Chiyoko Terada (C)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Katsuya Maebo (K)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Kohei Morita (K)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.
Department of Diagnostic Pathology, Nara Prefecture General Medical Center, Nara, Japan.

Eiwa Ishida (E)

Department of Diagnostic Pathology, Nara Prefecture General Medical Center, Nara, Japan.

Noriyoshi Sawabata (N)

Department of Thoracic and Cardio-Vascular Surgery, Nara Medical University, Kashihara, Japan.

Chiho Ohbayashi (C)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan.

Classifications MeSH